Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ARRY > SEC Filings for ARRY > Form 8-K on 9-Nov-2012All Recent SEC Filings

Show all filings for ARRAY BIOPHARMA INC

Form 8-K for ARRAY BIOPHARMA INC


9-Nov-2012

Entry into a Material Definitive Agreement, Other Events, Financial Statement


Item 1.01. Entry into a Material Definitive Agreement.

On November 9, 2012, Array entered into an Underwriting Agreement (the "Underwriting Agreement") with Jefferies & Company, Inc. and J.P. Morgan Securities LLC, as representatives of the several Underwriters named therein (collectively, the "Underwriters"). Subject to the terms and conditions of the Underwriting Agreement, Array agreed to sell to the Underwriters, and the Underwriters agreed to purchase from Array, an aggregate of 18,000,000 shares of Array's authorized but previously unissued common stock, par value $0.001 ("Common Stock"), at a public offering price of $3.65 per share. The resulting net proceeds to Array from this Common Stock offering are expected to be approximately $61.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Array. Array has also granted the Underwriters a 30-day option to purchase up to an aggregate of 2,700,000 additional shares of Common Stock to cover over-allotments, if any.
The Underwriters' obligations to purchase the shares is subject to the satisfaction of certain customary closing conditions, including receipt of legal opinions and approval of legal matters by their respective counsels. Array has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "Act"), or to contribute to the payments the Underwriters may be required to make in respect of these liabilities.

The closing of the sale of 18,000,000 of the shares is scheduled to occur on or about November 15, 2012. The shares have been registered pursuant to a registration statement on Form S-3 (Registration No. 333-178162) filed with the Securities and Exchange Commission (the "SEC") under the Act on November 23, 2011 and a registration statement on Form S-3 (Registration No. 333-184825) filed with the SEC under the Act on November 8, 2012.

The foregoing summary of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.



Item 8.01 Other Events.

The press release announcing the pricing of the public offering is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Forward-Looking Statements

This current report contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning the completion, timing and size of the proposed offering and other statements that are other than statements of historical facts. These statements involve significant risks and uncertainties. Because these statements reflect our current expectations concerning future events, actual events could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to: the risk that the financing may be delayed or may not occur due to market or other conditions and the satisfaction of customary closing conditions related to the proposed public offering. Additional information concerning these and other factors that may cause actual events to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of Array's most recent Annual Report on Form 10-K, in our other periodic reports and filings with the Securities and Exchange Commission and in the prospectus supplement related to the offering. We caution investors not to place undue reliance on the forward-looking statements contained in this current report. All forward-looking statements are based on information currently available to Array on the date hereof, and we undertake no obligation to revise or


update these forward-looking statements to reflect events or circumstances after the date of this current report, except as required by law.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.                                 Description
    1.1        Underwriting Agreement, dated November 9, 2012, by and among Array
               BioPharma Inc. and Jefferies & Company, Inc. and J.P. Morgan
               Securities LLC, as representatives of the several Underwriters party
               thereto
    5.1        Opinion of Gross Hartman LLC
   23.1        Consent of Gross Hartman LLC (contained in Exhibit 5.1)
   99.1        Press Release dated November 9, 2012 entitled "Array BioPharma
               Announces Pricing of Public Offering of Common Stock"


  Add ARRY to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ARRY - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.